| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2018-01-16 | AVXS-101 (adeno-associated virus serotype 9 expressing the human Survival Motor Neuron gene) | spinal muscular atrophy (SMA) Type 1 | 3 | Avexis (USA - IL) | Rare diseases - Genetic diseases - Neuromuscular diseases |
| 2018-01-16 | AVXS-101 (adeno-associated virus serotype 9 expressing the human Survival Motor Neuron gene) | spinal muscular atrophy (SMA) Type 1 | Avexis (USA - IL) | Rare diseases - Genetic diseases - Neuromuscular diseases | |
| 2018-01-15 | Cx601 (adipose derived allogeneic stem cell therapy) | perianal fistulas in Crohn's disease patients | 3 | Tigenix (Belgium) | Autoimmune diseases - Inflammatory diseases - Digestive diseases |
| 2018-01-11 | BI 1467335 (formerly known as PXS-4728A) | diabetic retinopathy | 2a | Boehringer Ingelheim (Germany) | Ophtalmological diseases |
| 2018-01-10 | GS030 | retinitis pigmentosa | 1-2 | Gensight Biologics (France) | Rare diseases - Genetic diseases - Ophtalmological diseases |
| 2018-01-09 | GNbAC1 | type 1 diabetes | 2a | Geneuro (Switzerland) | Autoimmune diseases - Metabolic diseases |
| 2018-01-08 | AR101 | peanut allergy | 3 | Aimmune Therapeutics (USA - CA) previously Allergen Research Corporation (ARC) | Allergic diseases |
| 2018-01-08 | Tesomet® (tesofensine) | Prader-Willi syndrome | 2a | Saniona (Denmark) | Rare diseases - Genetic diseases - Metabolic diseases |
| 2018-01-08 | MAGE A10c796T - autologous genetically modified T-cells expressing enhanced T cell receptors (TCRs) specific for MAGE A10 | locally advanced or metastatic (Stage IIIb or IV) non-small cell lung cancer (NSCLC) | 1-2 | Adaptimmune (UK) | Cancer - Oncology |
| 2018-01-08 | ACE 083 | facioscapulohumeral muscular dystrophy (FSHD) | 2 | Acceleron Pharma (USA - CA) | Rare diseases - Genetic diseases - Neuromuscular diseases |
| 2018-01-08 | intepirdine (RVT-101) | dementia with Lewy bodies (DLB) | 2 | Axovant Sciences (USA - NY) | Neurodegenerative diseases |
| 2018-01-05 | ISIS 678354 (AKCEA-APOCIII-LRx) | patients with hypertriglyceridemia and established cardiovascular disease | 2b | Akcea Therapeutics (USA - CA), a subsidiary of Ionis Pharmaceuticals (USA - CA) | Cardiovascular diseases |
| 2018-01-05 | M281 | autoimmune diseases | 1 | Momenta Pharmaceuticals (USA - MA) | Autoimmune diseases |
| 2018-01-04 | BioChaperone® glucagon exenatide | obesity | Adocia (France) | Metabolic diseases | |
| 2018-01-04 | BioChaperone® teduglutide | short bowel syndrome | Adocia (France) | Rare diseases - Gastrointestinal diseases | |
| 2018-01-04 | triheptanoin (UX007) | long-chain fatty acid oxidation disorder (LC-FAOD) | 2 | Ultragenyx Pharmaceutical (USA - CA) | Rare diseases - Cardiovascular diseases |
| 2018-01-04 | ABX464 | ulcerative colitis | 2a | Abivax (France) | Autoimmune diseases - Inflammatory diseases - Digestive diseases |
| 2018-01-03 | BAL101553 in combination with standard radiation | newly-diagnosed glioblastoma | 1 | Basilea Pharmaceutica (Switzerland) Adult Brain Tumor Consortium (ABTC) (USA) | Cancer - Oncology |
| 2018-01-03 | solid tumors including advanced or metastatic breast, ovarian, endometrial and urothelial carcinomas | 1 | Five Prime Therapeutics (USA - CA) | Cancer - Oncology | |
| 2018-01-03 | BAL101553 | advanced solid tumors including glioblastoma | 2a | Basilea Pharmaceutica (Switzerland) | Cancer - Oncology |
